Epidermolysis bullosa. Clinical aspects, pathology, and recent advances in research.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal; D000941:Antigens / Q000276:immunology; D001485:Basement Membrane / Q000276:immunology; D004274:DNA, Recombinant; D004820:Epidermolysis Bullosa / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D005347:Fibroblasts / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D005799:Genes, Dominant; D005808:Genes, Recessive; D006801:Humans; D003012:Microbial Collagenase / Q000378:metabolism; D008854:Microscopy, Electron; D010672:Phenytoin / Q000627:therapeutic use; D011296:Prenatal Diagnosis; D012176:Retinoids / Q000627:therapeutic use; D012867:Skin / Q000378:metabolism / Q000473:pathology; D013577:Syndrome
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D000941:Antigens; D004274:DNA, Recombinant; D012176:Retinoids; D010672:Phenytoin; D003012:Microbial Collagenase